NZ191171A - Lactate salts of glaucine and pharmaceutical compositions - Google Patents

Description

New Zealand Paient Spedficaiion for Paient Number 1 91171 Priority 7ft Gcrrp.'ois Cpccincstjon Fi'sd: '.If <"'cw''Wd*ha-- n p C , ' r-l ^ w-' . .

I ■ f I I I I I ■ ....

PubSiczlicn D P.O. Jcurr.3, L'o: 1911 V. S id ' ' -rsi JSi.% ■ i, Kj x ^ T > ■ t. •• Patents Form No. 5 NEW.ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION GLAUCINE LACTATE SALTS S/WE THE DOW CHEMICAL COMPANY, a corporation organized and existing under the laws of the State of Delaware, United States of America, of Midland, County of Midland, State of Michigan, United States of America' hereby declare the invention, for which $/we pray that a patent may be granted to ®a/us, and the method by- which it is to be performed, to be particularly described in and by the following statement " 1 *" (Isficwredi by I A.) t -1PI - 19117 1 LACTATE SALTS OF 1—AND d,1-GLAUCINE.

This invention is directed to the lactate salts of 1-glau-cine and d,l-glaucine, to pharmaceutical compositions containing said salts and to methods for using them as antitussive and analgesic agents.

Glaucine which has the following structure: possesses an asymmetric center indicated in the above formula with a star. Thus two optical isomers are possible.

Only one of them, the dextrorotatory form (d-glaucine) occurs naturally and can be isolated from the yellow poppy. The racemate, d,1-glaucine, can be synthesized from papave-> rine, following the procedure of Frank and Tietze, Ange-wandte Chemie (1967) pp 815-6, or according to a variety of other preparative methods such as those described by Chan and Maitland in J. Chem. Soc. (C) 1966, 753 or by Cava et al., in J. Org. Chem. 35^, 175 (1970). Separation of the two enantiomers can be carried out by conventional procedures such as using an optically active acid, for instance d— or 1-tartaric acid, to form the diaEtereoisomeric salts which can be separated by fractional crystallization. d-Glaucine hydrobromide and d-glaucine hydrochloride are known to have antitussive activity (Donev, Farmatsia (Sofia) 1962, _12y (4), p.17, and Aleshinskaya, Khim. Farm. Zh. lO, T(l) , pp. 144—147 (1976) and Chemical Abstracts 84_ : 159725-w). In addition, Aleshinskaya, supra, stated that glaucine derived 191171 from the yellow horned poppy (d-glaucine), prolonges hexenal and chloral hydrate sleep time in mice, and has analgesic activity at doses of 50—100 Jng/Kg, as well as adrenolytic activity.

More recent investigations proved th.at levorotatory and racemic isomers of glaucine hydrobromide have superior antitussive properties over the prior—art dextrorotatory form. (Belgian patent Ho.8GC.079); J As it can be ascertained, by the above formula,glaucine is structurally related to other plant alkaloids such as codeine. Codeine and related compounds, such as hydrocodone / are well known as antitussive and narcotic analgesic agents. Merck Index, Ninth Ed., Merck & Co., Rahway, N.J.(1976) monographs Nos. 2420-24 and 4672. Although these compounds are also well known to have a high potential for habituation or addiction, they remain the most potent and widely used antitussive agents. Antitussive agents are usually administered orally, most typically in the form of a liquid formulation such as an elixir, suspension or syrup, or in a solid lozenge or cough drop which is held in the mouth until it dissolves. In both cases the unpleasant bitter flavor of the alkaloid is known disadvantage of such agents. Various formulations have been developed to mask the unpleasant taste and after taste of codeine with varying degrees of success. None of these techniques however have been completely successful.

Glaucine, like codeine, has an unpleasant bitter taste. It has now surprisingly been found that 1-and d,1-glaucine lactate, besides having antitussive properties that are superior to the d-glaucine, have analgesic activity unexpectedly superior to that of d-glaucine coupled with a very low addic-GtWe potential, particularly, desirable solubility and stabi-l'i-ty properties, and unexpected flavour and palatability pro-perties which make them particularly useful orally. 191171 The novel lactate salts of the invention are crystalline solids which, are prepared by reacting 1-glaucine or d,l--glaucine (or mixtures thereof) in the form of the bases, with lactate ion under conditions adapted to the formation of lactate salts of organic bases. The salts can be obtained in crystalline solid form.

The compounds can be readily prepa'red by reacting the free glaucine base with lactic acid. The reaction proceeds readily in the presence of an inert organic solvent, such as acetone, ethanol, chlorofonri/methanol, diethyl ether, or ethyl acetate. The lactate salt typically forms as a precipi- ~ tate, which can be recovered by conventional techniques such as filtration or decantation and purified by conventional steps such as "recrystallization and washing.

The reaction is typically carried out by dissolving the free base glaucine in the inert organic solvent at a temperature from ambient temperature to the boiling point of the mixture, and adding an equimolar amount or an excess of lactic acid,.

Lactic acid can be employed in from about 0.5 to about 1 to 2 to 3 fold molar excess or more. Use of equimolar amounts is preferred.

When using excess lactic acidythe excess lactic acid precipitating with the product can be removed by recrystallization., Mixture of the 1- and d,1-glaucine lactate, 1-glaucine lactate salts, and the racemic salt are all useful as antitussive agents and analgesic agents, with similar desirable properties. For convenience it is generally preferred to use a single lactate salt, such as the d,1-glaucine lactate or 1--glaucine lactate, the preferred salt being d,1-glaucine lactate. The glaucine lactate salts are highly effective, orally active antitussive agents and also have analgesic activity when administered orally, combined with surprising palatability and 191171 desirable stability and solubility, and a useful freedom from undesired side effects, such, as addictive properties. They can be administered at dosages of from about 0.1 to about 40 milligrams or more per kilograms (mg/Kg) for antitussive effect, and from about 0.1 to about 60 mg/Kg for analgesic use, preferabily by oral administration. They are also active parenterally as antitussives and analgesics, by intraperitoneal injection, for example.

In practicing the method of the invention, an antitussive amount of one or more of the glaucine lactates is administered internally to an animal, typically a mammal in need thereof. Administration can be carried out either by a parenteral route, such as by intravenous, intraperitoneal, or intramuscular injection, or by - introduction into the gastrointestinal tract via oral or rectal administration, for example, or by oral administration of a glaucine lactate solution in the form of a throat spray, for example.

The antitussive amount of the compound, that is, the amount of the glaucine lactate sufficient to inhibit or alleviate coughing depends on various factors such as the size, type and age of the animal to be treated, the particular salt or . mixture of salts employed, the route and frequency of administration, the severity of cough (if any) and the causative agent involved, and the time of administration. Similar considerations apply to selection of the analgesic amount of the compound, that is the amount of the glaucine lactate sufficient to alleviate pain symptoms. The glaucine lactate salts are generally effective when administered orally as well as in parenteral dosages. For example, in antitussive evaluations in which codeine phosphate has an ED50 of 10.9 mg/Kg by intraperitoneal injection and an oral ED^Q of 86.6 mg/Kg, the 19117 1 oral and intraperitoneal ED_ ' s. obtained with. d,l-glau- bO cine lactate are 63.4 and 7.9 mg/Kg. In particular cases, the dosage to be administered can be ascertained by conventional- range finding techniques, for example, by obser~ ving th_e antitussive activity produced at different dosage rates.

Good antitussive resul"ts can be obtained when the salts are administered'orally at dosage rates from about 0.1 to about 0.2, to about 0.5 to about 1 to about 10 to about 20 to 25 to 30 to 40 to about 80 milligrams of glaucine salt compound per kilogram of animal body weight and at rates of 0.1 to 40 mg/Kg by intraperitoneal injection. It is generally desirable to administer individual dosages at the lowest amount which provides the desired cough suppression consonant with a convenient dosing schedule. Oral administration is the route generally preferred for administration of antitussive agents. The glaucine lactates of the invention thus combine high oral antitussive potency with palatability, making them particularly useful orally.

Dosage units adaptable to oral administration such as tablets, capsules, lozenges, elixirs, syrups and the like are preferred and the active glaucine lactate compound can be formulated in conventional timed release capsule or tablet formulations .

In using the compounds of the invention, the active glaucine lactate ingredient is preferably incorporated in a composition comprising a pharmaceutical carrier and from about 0.001 to about 95 percent by weight of the glaucine lactate salt compounds. The term "pharmaceutical carrier" reiers to known pharmaceutical excipients useful in formulating pharmacologically—active compounds for internal administration to animals, t 191171 and which, are substantially non-toxic and non-sensitizing under conditions of use. The compositions can be prepared by known techniques for the preparation of tablets, cap-... sules, cough drops, lozenges, troches,, suppositories, solutions, elixirs, syrups, emulsions, dispersions, wetta-ble and effervescent powders, sterile injectable compositions, and can contain suitable excipients known to be useful in the preparation of the particular type of composition desired.

The compounds may be administered in conjunction with other active ingredients or other antitussive or analgesic agents. Other active ingredients can include, for example, antihistamines, decongestants,, expectorants, mucolytic agents, bronchodilator and antibacterial agents or local anesthetics. Combinations of this type are generally useful for treating coughing or pain in combination with other symptoms .

Particularly desirable compositions are those prepared in . the form of dosage units, such as solid forms, including troches,' lozenges,,tablets, capsules, or measured volumes of liquid compositions, containing from about 0.1 milligram to about 20 to 30 milligrams of the glaucine salt per unit, for antitussive use and from about 0.1 milligram to about 30 to about 60 milligrams for analgesic use.

Example 1 — Preparation of d,1-glaucine lactate.

A. Two grams of d,1-glaucine was dissolved in 40 milliliters absolute alcohol (ethanol) at a temperature of 50^C, and the solution was added, with stirring, to a solution of 0.57 grams of 85 percent lactic acid diluted with 5 milliliters of ethanol. 191171 The resulting mixture was concentrated under vacuum, cooled; and diethyl ether was added to the concentrated solution until a precipitate formed. The white crystal— ^ line solid precipitate was collected by filtration and washed with diethyl ether. The d,1-glaucine lactate product (1.5 gram yield) was found to melt at 148.6-151^C. After recrystallization from eth.anol-dieth.yl ether, the purified salt was found to melt at 153.3^C. The product evidenced no 0 optical rotation, (/a/ =0.0 in water-100 mg/20 ml). 10 ~ D ' ,B. 5.6. Grams (0.02 mole) of d,1-glaucine was dissolved in 30 ml of alcohol USP (95 percent ethanol, 5 percent water)'. A solution of 2.5 grams (0.02 mole) - of 85 percent d,lrlactic acid (Zct/D=0) in 50 ml of alcohol USP was added to the glaucine solution with stirring. The solution was concentrated under reduced pressure, cooled in a refrigerator, and dry diethyl ether was added until crystal formation was complete. The crystalline product was separated by filtration, washed with diethyl ether, and found to melt at 147 -151^C.

(Yield 7.3 grams, 100 percent) The d,1-glaucine-d,1-lactate, product was dissolved in 130 ml alcohol USP at about 60^C, ' filtered, and cooled. Diethyl ether was added to precipitate the product, and the purified d,1-glaucine-d,1-lactate was found to melt at 153®C. (Yield 96 percent; assay 99.8 percent pure).

C. Elemental analysis of d,1-glaucine lactate: C,H,N-calculated 64.70, 7.01, 3.14; C,H,N-found 62.19, 7.17, 3.02. t 1.911 7 1 Example 2 - Separate groups of guinea pigs were orally administered various doses of a test compound, or distilled water for a control group. One hour after oral dosing, the guinea pigs were exposed to a 5 percent aerosol of citric acid for a 10 minute test period. The number of cough responses produced during the last five minutes of exposure to the citric acid aerosol was recorded and the dosage effected to suppress coughing in 50 percent of the guinea pigs (ED^) was calculated. An antitussive effect was recorded for a guinea pig when its total number of coughs during the 5 minute, test period were at least two standard deviation units below the mean number of coughs per guinea pig in the control group. In these operations, codeine phosphate was found to have an oral ED,_0 of 8 6.6; d-glaucine . * hydrobromide an ED,_0 of 89.0; and d,1-glaucine lactate an EDj.q of 63.4 milligrams per kilogram.

Example 3 - In an operation similar to that of Example 2, test compounds were administered to guinea pigs by intraperitoneal injection, with one group of guinea pigs 'receiving distilled water as a control. ED '-.s were calculated for antitussive activity in the citric acid aerosol test as described in Example 2. Codeine phosphate was found to have an EDj.q of 10.9 mg/Kg; d-glaucine hydrobromide an EDj.q of 10.0 mg/Kg; and d,1-glaucine lactate an ED^0 of 7.9 mg/Kg.

Example 4 - A cough syrup vehicle formulation was prepared containing the following pharmaceutically-acceptable excipients: t 1*1171 Exclpient - Amount Sugar (cane) 1600 grams Sorbitol solution USP 600 grams Eth.anol (Alcohol USP) 21 grams Water q.s. to 4 liters total The solubility of d,1-glaucine hydrobromide in this cough ✓ syrup vehicle was found to be 0.3 percent, or about 15 milligrams in a 5 milliliter dosage unit. The solubility of d,1-glaucine lactate was found to be 2 percent, or about 100 milligrams per 5 milliliter dosage unit.

Example 5 - Stability of d,1-glaucine lactate was examined in the syrup vehicle of Example 4. After one month at ambient 0 0 temperature, 40 C and 55 C, respectively, syrup formulated to contain 0.6 percent d,1-glaucine lactate was found to retain 98.8, 100.6, and 96.7 percent, respectively, of the original glaucine concentration.

Syrups containing codeine phosphate, 0.2 percent, contained 97.5, 104.5 or 100 percent, respectively, after one month at - o 0 ambient temperature, 40 C or 55 C. Syrups containing d,1-glaU- cine hydrobromide, 0.2 percent, resulted in assays of 99,96. and 89.5 percent, respectively, after one month at ambient temperature, 40^C and 55^C.

After three months, the percentage amount of antitussive agent remaining was as shown below. 19117\ Percentage Remaining after 3 .months at Compound Ambient 40°C 55°C d,l-Glaucine Lactate Codeine Phosphate d,l-Glaucine * HBr 104.1 97.0 97.4 101.3 101.1 88.4 100.8 93.3 91.4 Example 6 - In a procedure similar to that of Example 5/ syrup formulations were prepared, placed in amber glass bottles and transparent (flint) glass bottles, and held under conditions of ambient temperature with continuous exposure to light. (About 21.520- lux of combined fluorescent and incandescent light, for 24 hours/day).

After one month, the d,1-glaucine hydrobromide assay of amber bottles was 84 percent, that of flint glass bottles was 74.5 percent. d,l-Glaucine lactate in amber glass had an assay of 94 percent, in flint glass 80.6 percent. Codeine phosphate appeared stable in both types of container, with assays of 100 percent.

In other operations, crystalline d,1-glaucine lactate was found to retain over 99 percent of its original assay after 2 months storage at 40^C.

Example 7 - Physical dependency liability was evaluated in mice by the procedure of Saelens, et al., Arch. Int. Pharma-codyi^am, 190:213-218, 1971. In this procedure, mice are administered increasing doses of a test compound at intervals on two consecutive days. The last dosage on the second day is followed by intraperitoneal injection of the morphine antagonist, naloxone, at a dosage of 100 mg/Kg, and the mice are observed for characteristic . jumping behaviour indicative of opiate withdrawals or morphine antagonism. In 19117 1 these operations, morphine sulfate produced stimulation and Straub tail in mice, followed by jumping in 5 of 9 mice (96 jumps total) after naloxone treatment. Codeine phosphate produced Straub tail and stimulation, and naloxone—induced jumping in 2 of 6 mice (23 jumps total). d,l-Giaucine lactate produced no Straub tail at the highest dose (100 mg/Kg) a'nd no jumping behaviour in any o£ the ten mice tested.

Example 8 - Several d,1-glaucine salts were prepared as 0.2 percent (weight by volume) solutions in distilled water. The various salt solutions were evaluated for palatability by touching a few drops to the -tongue ^ In these operations, which included blind sampling by a trained flavor formula-tor experienced in flavoring of formulations containing agents such as codeine and dextromethorphan, the hydrobromide was characterized as objectionable with a bitter, sharp and metallic initial'taste which increased with time. The sulfate, maleate, citrate, acetate, pamoate and p-toluene-.sulfonate salts were similar to the hydrobromide and similarly objectionable. The salicylate and succinate salts-were ranked as more objectionable than the. hydrobromide. d,l-G'lau-cine lactate was found to lack the sharp, metallic flavor and to be unobjectionable.

Example 9 — A. A flavored cough syrup formulation is prepared to contain the_ following: * 19ft i/ t / .10 Ingredient Sucrose (100% invert sugar- rrdry Basis) Sorbitol syrup USP Glycerine Alcohol USP Piperonal Vanillin Ethyl.vanillin Ethyl maltol 1-menthol d,.1-glaucine lactate Purified water USP Amount 26.4 grams 10 milliliters (ml) 5 ml .4 ml ✓ .0 milligrams (mg) 7.5 mg 10.0 mg 7.5 mg 7 .5 mg 600 .mg q.s. to 100 ml total The syrup contains 0.6-percent (weight by volume) d,l--glaucine lactate and a 5 ml . dosage unit (1 teaspoon) contains 30 mg of active lactate salt. The syrup can be sealed into 5 ml plastic lined foil pouches, or filled into conventional glass bottles. Dosage units of 15 mg and 20 mg.per 5 ml dose can be made by using 300 or 400 mg of d,1-glaucine lactate or 1-glaucine lactate or mixtures thereof in the above formula.

B. Tablets are. prepared as follows: 40 grams 1-glaucine lactate; 150 grams of modified starch (Sta-Rex 1500) are 25 mixed and granulated with sufficient aqueous alcohol (75 percent water, 25 percent ethanol) to prepare a granulation. The granulation is dried and mixed with 15 grams starch USP; 1.5 grams stearic acid (40 mesh); 0.5 grams hydrogenated vegetable oil (40 mesh)x 3 grams colloidal silicon dioxide 3q and microcrystalline cellulose q.s. to 300 grams. The ingredients are mixed and compressed into 300 milligram tablets J 91 1 using 11/32 inch. (=8,7 .mm) tablet dies. The tablets contain 40 milligrams of 1-glaucine lactate each.

C. Capsules are prepared by blending 10 grams d,1-glaucine lactate, 3 grams colloidal silica; 2 grams stearic acid and 285 grams lactose; and filling the blend into No. 2 gelatin capsules, 300 milligrams per capsule. This provides 10 milligrams of glaucine lactate per capsule. Larger unit dosages,, such as 15, 20 or 25 mg, can be prepared by using 15, 20 or 25 grams glaucine lactate and lactose q.s. to 300 grams. Smaller dosages are similarly . prepared.

D. Troches are prepared, by mixing 30'grams d,1-glaucine lactate^43 5 grams powdered sugar and 35 grams powdered acacia; adding sufficient water to form a pliable mass; rolling the mass into a cylindrical shape and dividing the mass into 0.5 gram segments.

Example 10 - In other operations, various dosages of d,l--glaucine lactate were administered to groups of mice by the oral route or by intraperitoneal injection, and the dosage which is lethal to 50 percent of the mice (LD^^) was calculated from the mortality observations within 72 hours adter administration. The LD50 £or intraperitoneal injection was found to be 17 8 mg/Kg. The oral LD in thes D 0 operations was found to be 383 mg/Kg.

Example 11 - Test compounds were evaluated for analgesic activity in the phenyl-p-quinone mouse writhing test of

Claims (2)

1. -14-
2. 2*1171;Hendershot & Forsaith, J. Pharmacol. Exptl. Therap.;125 (3), 237 (1979). The test compounds were administered orally 30 minutes prior to the phenyl—p-quinone challenge.;In these operations, the oral ED ' s for d-glaucine hydro-;50;bromide, codeine phosphate, and d,1-glaucine lactate were found to be 3 4.0, 21.1 and 25.5 mg/Kg respectively.;191171;10;20;-15-;\jWHAT WE D-A3H;1. A glaucine salt selected from the group consisting of 1-glaucine lactate, d,1-glaucine lactate and mixtures thereof.;2. Compound of Claim 1 wherein the compound is d,l--glaucine lactate.;3. A composition comprising from about 0.01 percent by weight to about 95 percent by weight of a glaucine lactate compound selected from the group consisting of 1-25 -glaucine lactate, drl-glaucine lactate and mixtures thereof, in admixture with a pharmaceutical carrier.;4. Composition of Claim 3 wherein the composition is in dosage unit form adapted for oral administration as an antitussive agent, and wherein the composition contains from ofoo-B-t 0.1 to about 90 milligrams of the glaucine lactate per unit.;25;5. Composition of Claim 3 or 4 wherein the compound is d,1-glaucine lactate.;30;G v A method of alleviating coughing in emimaloj—eomt administering to an a Eussive amount of a glau-;Golocted from the group consisting of 1-glRnrine;BALDWIN, SON & CAREY;ATTORNEYS FOB THE 7tPPfc*5ANTS